ARO-ANG 3 Injection

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Homozygous Familial Hypercholesterolemia

Drug Information

Target Indication

Homozygous Familial Hypercholesterolemia

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ARWR

Arrowhead Pharmaceuticals, Inc.

Related Pipeline

Severe Hypertriglyceridemia

Familial Chylomicronemia

Homozygous Familial Hypercholesterolemia

IgA Nephropathy

Idiopathic Pulmonary Fibrosis